Posted on March 29, 2017

Avanzcare, the subsidiary of Al Sawari Holding in the medical sector, and Indivior, a leading global pharmaceutical specialized in addiction treatment with patient focus approach, have announced a new supply agreement. Under this agreement, Avanzcare will be the sole distributor of Indivior’s products to supply Qatar Health Institutions for the treatment of opioid dependent patients.

The announcement was made at Qatar-UK Business Forum held on Tuesday 28th March 2017. With this agreement Avanzcare will therefore be able to meet the latent need in Qatar for the delivery of a highly effective, novel treatment solutions. Avanzcare will be supplying Indivior’s  SUBOXONE® (buprenorphine and naloxone) Sublingual Film, SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet, a buprenorphine-based treatment for opioid dependence recognized by health authorities around the world as vital treatment options of opioid-dependent patients.

Avanzcare will be contributing to the recovery of patients suffering from addiction and helping them to be reintegrated into their communities and families. Avanzcare is committed to play an important role in ameliorating the perception and the stigma related to patients suffering from addiction in Qatar with the help of designated authorities and health bodies.

Avanzcare and Indivior sign 2 [].jpg